Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.41 USD
-0.28 (-2.21%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $12.41 0.00 (0.00%) 5:18 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 21 - 40 ( 145 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Cloudbreak Oncology Program Unveiled; Rezafungin''s January 24 AdCom Is the Next Key Stock Catalyst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Foundational CoM U.S. Patent Granted For CD388; Lancet Publication Highlights Rezafungin Pivotal Dataset; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rezafungin AdCom Set for January 24; We Anticipate an Unequivocally Positive Vote and a Meaningful CDTX Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Approaching Rezafungin PDUFA on March 22, 2023; Phase 2a CD388 Influenza Data in 1H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rezafungin PDUFA Date March 22, 2023, Under Priority Review; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Healthy Volunteer Dosed in Phase 2a Study of CD388 As Influenza Prophylactic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Awaiting NDA Acceptance to Confirm PDUFA Date; Updating Model Based on Melinta Agreement; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rezafungin NDA Submitted, PDUFA Expected in 1Q23; New Partner Melinta to Commercialize in the U.S.; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Dropping Coverage of Entasis Therapeutics (ETTX) and Cidara Therapeutics (CDTX)
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Highlights Cloudbreak Platform''s Potential in Two Major Therapeutic Areas; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Recap: Awaiting NDA Filing in Mid-2022; Phase 1 Safety and PK Data on CD388 in 2H22; Moderate PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ECCMID Presentations Highlight Rezafungin''s Safety
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD388 Phase 1 Trial Kicks Off As Expected; Dosing of First Cohort Already Completed; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; CD388 IND Filed; NDA Filing for Rezafungin on Track for Mid-2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; Rezafungin Regulatory Filings On Target for Mid-2022; Phase 1 Study of CD388 Begins in 1Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rezafungin''s PIM Designation May Enable Its Use in the U.K. Prior to Regulatory Approval; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD388 to Enter the Clinic For Seasonal and Pandemic Influenza With IND Acceptance; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E